Press release
Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Hodgkin's Lymphoma Pipeline Outlook [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hodgkin's Lymphoma Pipeline Report
* In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid Registered , CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.
* In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab.
* In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
* DelveInsight's Hodgkin's Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment.
* The leading Hodgkin's Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
* Promising Hodgkin's Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
Stay ahead with the most recent pipeline outlook for Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin's Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hodgkin's Lymphoma Emerging Drugs Profile
* AFM 13: Affimed Therapeutics
AFM13 is a first-in-class innate cell engager (ICE Registered ) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE Registered clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin's Lymphoma.
* AUR105 : Aurigene Oncology
AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.
The Hodgkin's Lymphoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment.
* Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market
Explore groundbreaking therapies and clinical trials in the Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Hodgkin's Lymphoma Drugs [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hodgkin's Lymphoma Companies
Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical
Hodgkin's Lymphoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hodgkin's Lymphoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hodgkin's Lymphoma Pipeline Report
* Coverage- Global
* Hodgkin's Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
* Hodgkin's Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
* Hodgkin's Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hodgkin's Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hodgkin's Lymphoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hodgkin's Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hodgkin's Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* AFM13: Affimed Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AUR105 : Aurigene Oncology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Hodgkin's Lymphoma Key Companies
* Hodgkin's Lymphoma Key Products
* Hodgkin's Lymphoma- Unmet Needs
* Hodgkin's Lymphoma- Market Drivers and Barriers
* Hodgkin's Lymphoma- Future Perspectives and Conclusion
* Hodgkin's Lymphoma Analyst Views
* Hodgkin's Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hodgkins-lymphoma-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4019198 • Views: …
More Releases from ABNewswire
JCFLOW Launches New Silicone Beads and Expands Wholesale Market Reach
JCFLOW [https://jcflowbeads.com/], a leading silicone bead factory store with operations in Las Vegas and China, is excited to announce the launch of its newest range of silicone beads, designed to meet the evolving needs of DIY crafters, small businesses, and creative entrepreneurs worldwide. Alongside the product launch, JCFLOW is implementing a strategic market expansion initiative to increase accessibility, offer customization options, and strengthen its position as a global leader in…
Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China In …
Renowned mosaic artist Shelly Hamill marks over 25 years of creating unique sculptures from recycled china, offering collectors a meaningful way to transform family heirlooms into displayable art. Trained as a Master of Mosaic in portraiture at the prestigious Orsoni studio in Venice, Italy, Hamill now expands her offerings with a new print-on-demand service and an innovative Print of the Month Club.
Shelly Hamill has spent more than a quarter century…
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Con …
Husband-and-wife Veteran team Matthew and Crystal Rorebeck have transformed their military experience and parenting journey into Earned Everyday, a Weatherford/Aledo athletic apparel brand with a powerful message for young athletes. Drawing from 46 combined years of military service and raising six children through deployment cycles, the retired Majors created a brand that teaches resilience, dedication, and the value of earning success.
A new athletic apparel brand with deep roots in military…
Pick-A-Part Jalopy Jungle Offers Top Dollar Cash for Unwanted Vehicles Across So …
Pick-A-Part Jalopy Jungle announces expanded cash-for-cars services across five locations in the Treasure and Magic Valleys, including Boise, Garden City, Nampa, Caldwell, and Twin Falls. The company provides free towing and guarantees competitive prices for unwanted vehicles while offering budget-friendly used auto parts for DIY mechanics.
Vehicle owners throughout the Treasure and Magic Valleys now have a convenient solution for selling unwanted cars, trucks, and other vehicles thanks to Pick-A-Part Jalopy…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
